Market research
PSH.F Sernova Corp
F EUR Healthcare
Latest close
As of 09 May 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 47M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.32
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA81732W1041
- Market cap
- 47M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.32
About
About Sernova Corp
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Research context
Sernova Corp appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PSH.F discussion.
5 years, 7 months ago
Sernova Corp is currently in a long term uptrend where the price is trading 29.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Sernova Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 9.6% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.8% to $-1M since the same quarter in the previous year.
Based on the above factors, Sernova Corp gets an overall score of 2/5.